III-01 Giulia Lestini
Model-based optimal robust design in pharmacometrics
Thursday 10:05-11:30 |
III-02 Lia Liefaard
Mixed effects modelling of dose-response cough count data
Thursday 10:05-11:30 |
III-03 Andreas Lindauer
Time-to-seizure modeling of the antiepileptic drug lacosamide used in monotherapy
Thursday 10:05-11:30 |
III-04 Ling Xue
Theory based PK-PD of S- and R-warfarin: influence of body size, composition and genotype
Thursday 10:05-11:30 |
III-05 Jesmin Lohy Das
Population pharmacokinetic and pharmacodynamic (PK/PD) modelling of emerging artemisinin resistance in Southern Myanmar
Thursday 10:05-11:30 |
III-06 Kurt Long
Identification of causal pathways determining the relationship between pathogen-specific infection and impaired growth among children < 59 months in Mirzapur, Bangladesh
Thursday 10:05-11:30 |
III-07 Dominik Lott
Population pharmacokinetics of the selective S1P1 receptor modulator ponesimod
Thursday 10:05-11:30 |
III-08 Gaohua Lu
A Novel Mechanistic Approach to Predict the Steady State Volume of Distribution (Vss) using the Fick-Nernst-Planck Equation
Thursday 10:05-11:30 |
III-09 Sreenath M Krishnan
Population modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib
Thursday 10:05-11:30 |
III-10 Vincent Madelain
Favipiravir pharmacokinetics in non-human primates: insights for future efficacy studies against hemorrhagic fever viruses
Thursday 10:05-11:30 |
III-11 Mats Magnusson
Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis
Thursday 10:05-11:30 |
III-12 Adedeji Majekodunmi
Mechanistic modelling of naive CD4+ T cell homeostasis in HIV-infected children on anti-retroviral therapy
Thursday 10:05-11:30 |
III-13 Victor Mangas-Sanjuan
Exploring Inter-study variability in the context of modeling unperturbed xenograft data
Thursday 10:05-11:30 |
III-14 Vikash Mansinghka
BayesDB Marcro Indicator Explorer ensemble models for growth outcome country phenotyping
Thursday 10:05-11:30 |
III-15 Ben Margetts
Modelling Severe Human Cytomegalovirus Infections in an Immunocompromised Paediatric Patient Population
Thursday 10:05-11:30 |
III-16 Amelie Marsot
Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers
Thursday 10:05-11:30 |
III-17 Lisa Martial
Population PK model and pharmacokinetic target attainment of micafungin in ICU patients
Thursday 10:05-11:30 |
III-18 Emma Martin
Modelling based methods to account for dropout in xenograft experiments
Thursday 10:05-11:30 |
III-19 Jean-Marie Martinez
Modelling and simulation of alirocumab – Part 1: Population pharmacokinetic analysis using a Michaelis-Menten approximation of the target-mediated drug disposition model
Thursday 10:05-11:30 |
III-20 Paolo Mazzei
Population exposure-response modeling of oral nepadutant administration in infants with colic
Thursday 10:05-11:30 |
III-21 Litaty Céphanoée Mbatchi
Pharmacokinetics modelling of temsirolimus and its active metabolite
Thursday 10:05-11:30 |
III-22 Johanna Melin
Semi-mechanistic modelling of the nonlinear hydrocortisone pharmacokinetics to enable extrapolation into paediatric patients
Thursday 10:05-11:30 |
III-23 Evgeny Metelkin
Development of immune responce template forsystems pharmacology modeling of immunotherapy in oncology
Thursday 10:05-11:30 |
III-24 Jonathan Mochel
Pharmacodynamics of the renin-angiotensin aldosterone system and blood pressure in relation to food intake in dogs
Thursday 10:05-11:30 |
III-25 Shuhua Hu
Use of interim analysis to improve efficiency of clinical trial simulations in treatment comparison trial design studies
Thursday 10:05-11:30 |
III-26 Pablo Morentin Gutierrez
A population pharmacokinetic-pharmacodynamic model for AZD7687: Effects on plasma triacylglycerol after oral lipid tolerance test
Thursday 10:05-11:30 |
III-27 Michael Morimoto
A quantitative physiologic model of the interaction of nutrition and infection in determining the energy available for growth
Thursday 10:05-11:30 |
III-28 Samer Mouksassi
Primary microcephaly: do all roads lead to Rome?
Thursday 10:05-11:30 |
III-29 Morris Muliaditan
Prediction of the exposure of anti-tuberculosis drugs in lung tissue: implications for dose selection
Thursday 10:05-11:30 |
III-30 Zufar Muliukov
Modeling the effect of ranibizumab on central retinal thickness in patients with wet age-related macular degeneration
Thursday 10:05-11:30 |
III-31 Silke Gastine
Population Pharmacokinetics of Voriconazole in pediatric cancer patients - assessing new dosing strategies
Thursday 10:05-11:30 |
III-32 C.J. Musante
The International Society of Pharmacometrics’ Special Interest Group on Quantitative Systems Pharmacology: Developing a community and advancing a field
Thursday 10:05-11:30 |
III-33 Karin Nelander
Longitudinal dose-response modelling as primary analysis of a clinical study
Thursday 10:05-11:30 |
III-34 Xavier Nicolas
Modelling and simulation of alirocumab - Part 2: Population pharmacokinetic/pharmacodynamic analysis using an indirect response model to link drug concentrations with LDL-C
Thursday 10:05-11:30 |
III-35 Jaeseong Oh
Simultaneous population pharmacokinetic analysis of VVZ-149 and its active metabolite in healthy volunteers
Thursday 10:05-11:30 |
III-36 Boram Ohk
Population Pharmacokinetic modeling of Tacrolimus in Healthy Korean Subjects
Thursday 10:05-11:30 |
III-37 Andrés Olivares-Morales
Combining population with physiologically-based pharmacokinetic (PBPK) models for oral drug absorption: Predicting the segmental bioavailability differences of R-oxybutynin and its main metabolite using a middle out approach.
Thursday 10:05-11:30 |
III-38 Per Olsson Gisleskog
Predicting the effects of combining broadly neutralizing antibodies (bNabs) binding to different HIV viral epitopes
Thursday 10:05-11:30 |
III-39 Mohamed Omari
Modelling of glucose-insulin metabolism and its effect on the estrous cycle in bovine
Thursday 10:05-11:30 |
III-40 Sean Oosterholt
Model-based extrapolation and dosing recommendation for raxibacumab in children from birth to <18 years of age
Thursday 10:05-11:30 |
III-41 Stine Timmermann Ottesen
Analysing the contribution to receptor occupancy from active metabolites
Thursday 10:05-11:30 |
III-42 - -
Delineation of the treatment effect of methotrexate when used in combination therapy for rheumatoid arthritis
Thursday 10:05-11:30 |
III-43 Theodoros Papathanasiou
Population modelling of the synergistic effects of morphine and gabapentin in the rat: a response surface approach
Thursday 10:05-11:30 |
III-44 Zinnia Parra-Guillen
Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment
Thursday 10:05-11:30 |
III-45 Sophie Peigné
Optimal design in the analysis of a clinical study in paediatric population
Thursday 10:05-11:30 |
III-46 Nathalie Perdaems
PK/PD modelling: a usefull tool to train people to better design in vivo chronic study in ob/ob mice
Thursday 10:05-11:30 |
III-47 Belén Pérez Solans
Markov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients
Thursday 10:05-11:30 |
III-48 Alejandro Pérez-Pitarch
Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes Mellitus: Modelling Rate and Severity of Hypoglycemic Events
Thursday 10:05-11:30 |
III-49 Carlos Perez-Ruixo
Population pharmacokinetics and antiviral efficacy in neonatal lambs: evidence of rapid maturation and auto-induction drug effect in metabolic clearance
Thursday 10:05-11:30 |
III-50 Caroline Petit
Early phase dose-finding designs for bridging studies in pediatrics
Thursday 10:05-11:30 |
III-51 Séverine Petitprez
Population pharmacokinetic meta-analysis of seven antiretroviral drugs
Thursday 10:05-11:30 |
III-52 Tatiana Petukhova
Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics
Thursday 10:05-11:30 |
III-53 Thomas Peyret
A mechanistic maternal-fetal growth energy budget model
Thursday 10:05-11:30 |
III-54 Kimba Eddy Phongi
Population Pharmacokinetics of the Novel Antimalarial OZ439
Thursday 10:05-11:30 |
III-55 Chiara Piana
A novel model-based methodology for the evaluation of abuse potential
Thursday 10:05-11:30 |
III-56 Philippe Pierrillas
From mouse to human: comparison of interspecies translational strategies using integrative semi-mechanistic PK-PD models and PBPK-PD modeling to forecast efficacious clinical dose
Thursday 10:05-11:30 |
III-57 Teun Post
Application of a Shiny Workflow in Cardiovascular Effects Evaluations
Thursday 10:05-11:30 |
III-58 Manuel Prado-Velasco
Bridging the gap between open and specialized modelling tools in PBPK/PK/PD with PhysPK/EcosimPro modelling system: PBPK model of methotrexate and 6-mercaptopurine in humans with focus in reusability and multilevel modelling features
Thursday 10:05-11:30 |
III-59 Tim Preijers
In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients
Thursday 10:05-11:30 |
III-60 Claire Pressiat
Population pharmacokinetics of cotrimoxazole In West African HIV-infected children
Thursday 10:05-11:30 |
III-61 Angelica Quartino
Comparisons of Multiple Exposure-Response Methodologies in Oncology
Thursday 10:05-11:30 |
III-62 Rachel Rose
Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis.
Thursday 10:05-11:30 |
III-63 Christian Radke
Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis
Thursday 10:05-11:30 |
III-64 Christian Hove Claussen
Automated modeling workflow with LaTeX: using the new Pfizer Report Tool
Thursday 10:05-11:30 |
III-65 Isabel Reinecke
Changes in endogenous estradiol concentrations explain fluctuations in levonorgestrel (LNG) concentrations during continuous treatment with LNG releasing intravaginal rings
Thursday 10:05-11:30 |
III-66 Su-jin Rhee
A population pharmacokinetic analysis of levetiracetam in patients with epilepsy
Thursday 10:05-11:30 |
III-67 Sophie Rhodes
Previous BCG vaccination associated with variation in Mycobacterial-specific immune response: a modelling study
Thursday 10:05-11:30 |
III-68 Jakob Ribbing
Predicting reductions in chronic obstructive pulmonary disease (COPD) exacerbations from FEV1 – A model-based meta-analysis of literature data from controlled randomized clinical trials
Thursday 10:05-11:30 |
III-69 Camille Riff
First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery
Thursday 10:05-11:30 |
III-70 Clémence Rigaux
Parasitemia clearance modeling following Ferroquine administration in P. Falciparum infected patients
Thursday 10:05-11:30 |
III-71 Christelle Rodrigues
Population pharmacokinetics of oxcarbazepine and its 10-monohydroxy derivative in epileptic children
Thursday 10:05-11:30 |
III-72 Stefan Roepcke
Model-based analysis of monkey PK and PD data of a therapeutic cell depleting human monoclonal antibody – Preparing for clinical trials
Thursday 10:05-11:30 |
III-73 Amit Roy
Evaluating effectiveness of case-matching for exposure-response analysis
Thursday 10:05-11:30 |
III-74 Yue Ruan
Bayesian hierarchical model of glucose-insulin regulation over 12-week home use of closed-loop insulin delivery
Thursday 10:05-11:30 |
III-75 Muhammad Waqas Sadiq
Acute tolerance and rebound modelling with competitive interaction of mineralcorticoid driven urinary sodium excretion effects in the rat
Thursday 10:05-11:30 |
III-76 Richard Pugh
Data Science & Big Data: An Opportunity or a threat for Pharmacometrics?
Thursday 10:05-11:30 |
